皓宸医疗(002622) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥210,007,224.10, representing a 5.49% increase year-over-year, while year-to-date revenue reached ¥523,639,966.97, up 27.43% compared to the same period last year[7] - Net profit attributable to shareholders for Q3 2023 was ¥8,700,983.06, a decrease of 49.00% year-over-year, while year-to-date net profit was ¥16,321,536.90, an increase of 220.90%[7] - The basic earnings per share for Q3 2023 was ¥0.0103, down 49.26% year-over-year, while year-to-date earnings per share increased by 220.50% to ¥0.0194[7] - Total operating revenue for the period reached ¥523,639,966.97, an increase of 27.4% compared to ¥410,933,863.05 in the previous period[32] - The net profit for Q3 2023 was CNY 35,166,529.21, a significant increase compared to a net loss of CNY 16,412,288.43 in the same period last year, representing a turnaround in performance[33] - Operating profit reached CNY 34,527,160.94, compared to an operating loss of CNY 18,913,070.51 in the previous year, indicating a strong operational recovery[33] - Total comprehensive income for the period was CNY 37,234,881.52, compared to a loss of CNY 16,820,379.03 in the same quarter last year, highlighting a positive shift in overall financial health[33] Cash Flow and Assets - The company reported a significant increase in cash flow from operating activities, with a year-to-date net cash flow of ¥45,761,050.12, up 992.70%[7] - Cash flow from operating activities generated a net cash inflow of CNY 45,761,050.12, a substantial improvement from a net outflow of CNY 5,126,157.03 in the prior year[34] - The company's total assets as of September 30, 2023, were ¥1,692,740,060.68, up from ¥1,635,408,931.74 at the beginning of the year, representing a growth of 3.3%[31] - Current assets totaled ¥339,431,839.66, an increase from ¥307,676,294.97 at the start of the year, indicating an increase of 10.3%[29] - The cash and cash equivalents increased to ¥155,890,319.05 from ¥120,113,833.90, a growth of 29.7%[29] - The company reported cash and cash equivalents of CNY 150,098,941.99 at the end of the quarter, an increase from CNY 171,162,846.74 at the end of the previous quarter[35] Expenses and Liabilities - Total operating costs amounted to ¥520,216,907.68, up from ¥455,279,109.29, reflecting a rise of 14.3%[32] - The company incurred a total operating expense of CNY 499,310,215.94, which is an increase compared to CNY 424,450,569.18 in the previous year, indicating higher operational costs[35] - The company's total liabilities reached ¥1,086,751,576.23, compared to ¥1,066,655,328.80 previously, reflecting a rise of 1.8%[31] - The company reported a significant increase in accounts payable, which rose to ¥67,316,252.37 from ¥47,915,739.13, an increase of 40.5%[30] Shareholder Information - Total number of common shareholders at the end of the reporting period is 46,048[20] - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, holds 23.81% of shares, totaling 200,000,000 shares[20] - The second-largest shareholder, Shaanxi International Trust Co., Ltd., holds 3.84% of shares, totaling 32,263,200 shares[20] - The company has a total of 8 major shareholders with significant stakes, including natural persons and investment funds[21] Legal and Regulatory Matters - The company is actively negotiating with creditors and courts to resolve the freezing of bank accounts and assets[24] - The company has disclosed multiple announcements regarding potential changes in control and ongoing legal matters[21][23] - The company is exploring legal options regarding ongoing litigation to protect shareholder interests[23] - The company will continue to monitor and disclose any developments related to the frozen assets and bank accounts[24] Research and Development - Research and development expenses increased by ¥488,000, representing an 84.33% increase compared to the same period last year[12] - Research and development expenses increased significantly to ¥10,675,860.37, compared to ¥5,791,641.62 in the previous period, marking an 84.5% increase[32]